PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31958741-3	2020	In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation.	Lidocaine	34-43	interleukin 6	Mus musculus	161-174	
31958741-3	2020	In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation.	Lidocaine	34-43	interleukin 6	Mus musculus	176-180	
31958741-3	2020	In this study, we have shown that lidocaine dose-dependently inhibits lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in macrophages and that lidocaine protects mice from LPS-induced inflammation.	Lidocaine	206-215	interleukin 6	Mus musculus	176-180	
31958741-4	2020	Moreover, we have demonstrated that lidocaine reduces the release of TNF-alpha and IL-6 through the reduction of the expression of GLUT1 and HK2 to further suppress HIF1alpha-induced aggravation of inflammatory cascades.	Lidocaine	36-45	interleukin 6	Mus musculus	83-87	
31209627-7	2019	CCI induced an significant increase of IBA1+ microglia accompanied by the increase of inflammatory cytokines IL-6 and IL-1beta, which were suppressed after lidocaine administration.	Lidocaine	156-165	interleukin 6	Mus musculus	109-113